{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105159","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.852711+00:00","generated_at":"2026-05-17T17:17:33.002795+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sutro Q2 revenue $63.7M; cash $205.1M; STRO-004 IND on track for H2 2025","bullets":["Q2 revenue $63.7M, up 148% YoY, driven by Astellas collaboration and Ipsen deferred revenue recognition.","Cash, equivalents and marketable securities $205.1M; cash runway into early 2027.","R&D and G&A expenses $48.7M (down 35% YoY); restructuring costs $18.4M from luvelta deprioritization.","STRO-004 FIH trial on track for H2 2025; STRO-006 clinical in 2026; dual-payload ADC IND filing in 2027.","Astellas milestone triggered $7.5M payment; Ipsen terminates STRO-003; Greg Chow appointed CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105159","json":"https://secwatch.observer/filing/0000950170-25-105159.json","markdown":"https://secwatch.observer/filing/0000950170-25-105159.md","text":"https://secwatch.observer/filing/0000950170-25-105159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/0000950170-25-105159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/stro-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:17:33.002795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}